JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB287633

Human MYB knockout MCF7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

MYB KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

C myb, MYB proto-oncogene transcription factor, MYB_HUMAN, ONCOGENE AMV, Oncogene MYB, Proto-oncogene c-Myb, Transcriptional activator Myb, c-myb protein (140 AA), c-myb10A_CDS, c-myb13A_CDS, c-myb14A_CDS, c-myb8B_CDS, c-myb_CDS, efg, v-myb avian myeloblastosis viral oncogene homolog

1 Images
Next Generation Sequencing - Human MYB knockout MCF7 cell line (AB287633)
  • NGS

Lab

Next Generation Sequencing - Human MYB knockout MCF7 cell line (AB287633)

124 bp deletion (allele 1) and 128 bp deletion (allele 2) in exon 6, CCDS47481.1

Key facts

Cell type

MCF7

Species or organism

Human

Tissue

Breast

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type MCF7 cell line (ab288560). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
MYB
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • Slow to trypsinise.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 5-7x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

MEM + 10% FBS + 0.01 mg/ml bovine insulin

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The c-Myb protein also known as Myb MYB or c-myb acts mechanically as a transcription factor that regulates the expression of target genes. It plays a role in cellular processes like proliferation differentiation and apoptosis by binding to specific DNA sequences. c-Myb has a molecular mass of roughly 75 kDa. It predominantly expresses in hematopoietic cells where it significantly influences gene transcription activity. Also it appears in some epithelial tissues indicating its versatile role in different cell types.
Biological function summary

The protein serves as a master regulator in the development of various cell types. It is not part of a traditional complex but interacts with other proteins to exert its function such as binding with co-activators or repressors to modulate gene expression. c-Myb controls the transcription of genes that are critical for cell cycle regulation and differentiation especially in the context of blood cell lineages. The protein is particularly influential in the production of red blood cells and white blood cells.

Pathways

C-Myb fits integrally into known hematopoietic signaling cascades and the Wnt signaling pathway. It works alongside other proteins like cyclin-dependent kinase (CDK) family members and transcription factor GATA-1 to modulate lineage-specific gene expression. Through its regulatory actions c-Myb influences the activation of downstream effectors that propagate signals essential for maintaining cellular functions within these pathways. The modulation of these pathways underlines its role in cell fate decisions.

Studies link c-Myb to several forms of leukemia and colon cancer. In leukemia aberrant expression of c-Myb disrupts normal hematopoiesis contributing to the uncontrolled proliferation of immature blood cells. The abnormal interactions between c-Myb and proteins like Bcl-2 can lead to enhanced cellular survival further promoting malignant conditions. In colon cancer c-Myb overexpression influences tumor growth and progression often acting alongside other oncogenic factors to enhance disease severity.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com